| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
Quzyttir is owned by Jdp.
Quzyttir contains Cetirizine Hydrochloride.
Quzyttir has a total of 5 drug patents out of which 0 drug patents have expired.
Quzyttir was authorised for market use on 04 October, 2019.
Quzyttir is available in solution;intravenous dosage forms.
Quzyttir can be used as method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria, treatment of acute urticaria, method of treatment in patients with concomitant angioedema.
The generics of Quzyttir are possible to be released after 28 February, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 04, 2022 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2019
Treatment: Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Treatment of acute urticaria; Method of treatment in...
Dosage: SOLUTION;INTRAVENOUS
QUZYTTIR family patents
